PRJNA662505
genome-wide CRISPR/Cas9 screen using survival to a NET-inducing stimulus
PLB-985 human myeloid cell line, differentiated (in RPMI 2.5% FCS, 0.5% dimethylformamide, P/S and glutamine) for 7 days. Mock-treated and PMA-stimulated for 16h to induce cell death via NET formation. Survivors were FACS-sorted for DNA extraction and sequencing